mRNA? No thank you. As far as I'm concerned, you would have to be brain dead before taking anything that is based on mRNA. Fool me once, shame on you. Fool me twice, and I'm dead.
Important context, Vinay, before comparing hazard ratios: these trials enrolled very different populations. Nearly a third of the vaccine trial patients had stage II melanoma, and many had stage III microscopic nodal disease. Neither group would have qualified for S1801 or NADINA, which required clinically detectable disease. So many of these patients would not have qualified for neoadjuvant immunotherapy.
mRNA? No thank you. As far as I'm concerned, you would have to be brain dead before taking anything that is based on mRNA. Fool me once, shame on you. Fool me twice, and I'm dead.
NEVER AGAIN.
Important context, Vinay, before comparing hazard ratios: these trials enrolled very different populations. Nearly a third of the vaccine trial patients had stage II melanoma, and many had stage III microscopic nodal disease. Neither group would have qualified for S1801 or NADINA, which required clinically detectable disease. So many of these patients would not have qualified for neoadjuvant immunotherapy.
That last line reminds me of a saying I love to use - Prayer works great for a cavity as long as one prays on the way to the dentist!